These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35832439)

  • 1. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.
    Spagnuolo A; Maione P; Gridelli C
    Transl Lung Cancer Res; 2022 Jun; 11(6):1199-1216. PubMed ID: 35832439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
    Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
    Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
    Oya Y; Imaizumi K; Mitsudomi T
    Lung Cancer; 2024 Aug; 194():107886. PubMed ID: 39047616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
    Karachaliou A; Kotteas E; Fiste O; Syrigos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KRAS
    Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
    Drugs; 2024 May; 84(5):527-548. PubMed ID: 38625662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
    Shu CL; Liu YL
    Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS G12C Mutations in NSCLC: From Target to Resistance.
    Addeo A; Banna GL; Friedlaender A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34064232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KRAS in Non-Small Cell Lung Cancer.
    Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
    Front Oncol; 2021; 11():792635. PubMed ID: 35083149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.
    Li JX; Li RZ; Ma LR; Wang P; Xu DH; Huang J; Li LQ; Tang L; Xie Y; Leung EL; Yan PY
    Front Pharmacol; 2022; 13():875330. PubMed ID: 35517800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
    Palma G; Khurshid F; Lu K; Woodward B; Husain H
    NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.